Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | AXL positive |
Therapy | ADCT-601 |
Indication/Tumor Type | esophageal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
AXL positive | esophageal cancer | sensitive | ADCT-601 | Preclinical - Pdx | Actionable | In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive esophageal cancer cell line in culture and resulted in complete responses in 2/8, partial responses in 5/8, and tumor-free survival in 2/8 patient-derived xenograft (PDX) models (PMID: 35086955). | 35086955 |
PubMed Id | Reference Title | Details |
---|---|---|
(35086955) | Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. | Full reference... |